Cover Image
市場調查報告書

東亞的醫藥品市場 - 2016-2026年:日本、台灣、韓國的各藥物分類成長預測

East Asian Pharmaceutical Market 2016-2026: Prospects for Growth Among Drug Classes in Japan, Taiwan and Korea

出版商 Visiongain Ltd 商品編碼 353586
出版日期 內容資訊 英文 132 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
東亞的醫藥品市場 - 2016-2026年:日本、台灣、韓國的各藥物分類成長預測 East Asian Pharmaceutical Market 2016-2026: Prospects for Growth Among Drug Classes in Japan, Taiwan and Korea
出版日期: 2016年03月03日 內容資訊: 英文 132 Pages
簡介

本報告以東亞的醫藥品市場為焦點,提供2016-2026年期間其收益變化預測,依據近幾年的產業成績、成長率、市場佔有率等資料,提供定性分析及商業發展考察,以及日本、台灣、韓國的各主要市場領域(學名藥、創始藥、OTC、生技仿製藥)的收益預測,主要企業的成長性,產業發展的課題等獨有的最新資訊彙整。

第1章 報告概要

  • 東亞醫藥品市場概要
  • 東亞醫藥品市場報告的市場區隔
  • 報告的利用價值
  • 報告使用方法
  • 由於報告被闡明的主要的疑問點
  • 報告的推薦用戶層
  • 調查方法
  • 很好地某問題(FAQ)
  • Visiongain出版的相關報告
  • 關於Visiongain
  • 換算比率

第2章 簡介 - 東亞的醫藥品市場

  • 各國市場定義
    • 日本
    • 台灣
    • 韓國
  • 其他醫藥品市場定義
    • 創始藥
    • 學名藥
    • OTC
    • 生技仿製藥
  • 全球醫藥品市場相關簡介
  • 醫藥品認證規定
    • 日本
    • 台灣
    • 韓國
  • 東亞醫藥品市場預測

第3章 日本的醫藥品市場

  • 日本的保健制度
    • 費用負擔和醫療制度
    • 學名藥的普及擴大 - 政策問題
    • 健康管理技術評估
  • 日本的醫藥品市場
    • 日本的醫藥品市場預測
  • 日本的醫藥品市場 - 各領域構成比
  • 日本的學名藥市場
  • 日本的創始藥市場
  • 日本的OTC市場
  • 日本的生技仿製藥市場

第4章 日本的醫藥品市場定性分析

  • 日本的醫藥品市場SWOT分析
    • 優勢
      • 對為收益維持貢獻的品牌商品的好感
      • 醫療機關使用率高
      • 高齡化加速的需求
    • 弱點
      • 由於行政的價格設定而縮小的淨利率
      • 由於學名藥的普及擴大而使專利失效創始藥的收益受損
      • OTC市場規定與消費者的低意願
    • 機會
      • 由於高齡化使高級醫藥品需求擴大
      • 可能在再生醫療領域的發展的新制度 - 先驅改革
      • 透過TPP(環太平洋策略性經濟聯合協定)的貿易機會擴大
    • 威脅
      • 可從人口動態發生的資金問題
      • 由於生技仿製藥的利用擴大使醫藥品市場收益減少的可能性
  • 日本醫藥品市場的波特五力分析
  • 日本國內的有力醫藥品廠商

第5章 台灣的醫藥品市場

  • 台灣的保健制度
    • 費用負擔和醫療制度
    • 健康管理技術評估
  • 台灣的醫藥品市場
    • 台灣的醫藥品市場預測
  • 台灣的醫藥品市場 - 各領域構成比
  • 台灣的學名藥市場
  • 台灣的創始藥市場
  • 台灣的OTC市場
  • 台灣的生技仿製藥市場

第6章 台灣的醫藥品市場定性分析

  • 台灣的醫藥品市場SWOT分析
    • 優勢
      • 穩定的國民健康保險的水準
      • 醫療設施的高的信用、使用率
      • 逐漸前進的高齡化
    • 弱點
      • 傳統藥物的強力存在感
      • 由於政策造成的禁運與不完全的二國間貿易
    • 機會
      • 高齡化擴大與其伴隨的醫藥品需求
      • 保證支援製藥、生物科技產業的新政權
      • 台灣推動作為醫療旅行目的地
    • 威脅
      • 中國對台灣的國際關係的影響
      • 亞洲內競爭國帶動醫藥品市場的成長
  • 台灣醫藥品市場的波特五力分析
  • 台灣的有力醫藥品廠商

第7章 韓國的醫藥品市場

  • 韓國的保健制度
    • 費用負擔和醫療制度
  • 韓國的醫藥品市場
  • 韓國的醫藥品市場 - 各領域構成比
  • 韓國的學名藥市場
  • 韓國的創始藥市場
  • 韓國的OTC市場
  • 韓國的生技仿製藥市場

第8章 韓國的醫藥品市場定性分析

  • 韓國的醫藥品市場SWOT分析
  • 韓國醫藥品市場的波特五力分析
  • 韓國的有力醫藥品廠商

第9章 採訪

  • 採訪 - 澤井製藥(東京)

第10章 結論

  • 東亞的醫藥品市場
    • 高齡化與高漲的醫療支出的壓力
    • 速度減低的經濟發展
  • 日本的醫藥品市場
  • 台灣的醫藥品市場
  • 韓國的醫藥品市場
目錄
Product Code: PHA0096

What can be expected from the East Asian pharmaceutical market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects there.

Our 132-page report provides 67 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall regional market and national level. You will see financial results, an interview, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects

Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces analysis) and commercial developments.

See revenue forecasts for the leading submarkets and indications

How will submarkets perform to 2026? Our study forecasts revenues in Japan, Taiwan and Korea for the following drug classes:

  • Generic Drugs
  • Originator Drugs
  • OTC Drugs
  • Biosimilars

image1

Leading companies and potential for market growth

Overall revenue for the East Asian pharmaceutical market will reach $121.5bn in 2020, our work forecasts. We predict strong revenue growth through to 2026. The ageing of the population in each country results in strong opportunities for increased pharmaceutical sales.

Our work analyses the key companies in the market. See visiongain's analysis of 13 leading companies, including these:

  • Takeda
  • Astellas Pharma
  • Otsuka Pharmaceutical
  • Daiichi Sankyo
  • Eisai Co.
  • Standard Chem and Pharma Co.
  • Chunghwa Chemical and Pharmaceutical
  • Yung Shin
  • TWi Biotechnology
  • OBI Pharmaceutical
  • Daewoong Pharmaceutical
  • Samsung Bioepis
  • Celltrion

A company profile gives you the following information where available:

  • Discussion of a company's activities and outlook
  • Company news relevant to the market

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

image2

What issues will affect the East Asian Pharmaceutical industry?

Our new report discusses issues and events affecting the East Asian pharmaceutical market. You will find discussions, including qualitative analyses:

  • Trends driving increased pharmaceutical demand
  • Government programmes to reduce pharmaceutical spending

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the East Asian Pharmaceutical Market 2016-2026 report helps you

In summary, our 132-page report gives you the following knowledge:

  • Revenue forecasts to 2026 for the East Asian pharmaceutical market - discover the industry's prospects, finding promising places for investments and revenues
  • Revenue forecasts to 2026 for the leading national markets - Japan, Taiwan and Korea
  • Revenue forecasts to 2026 for submarkets in each nation - discover prospects for leading generics, originator drugs, OTC products and biosimilars in each country. Identify the key trends driving and restraining growth in the market, including government policy and economic conditions relevant to the market.
  • Assessment of 13 leading companies - revenue (where available), news and upcoming product releases
  • Discussion of what stimulates and restrains the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

visiongain's study is for everybody needing commercial analyses for the East Asian pharmaceutical market and leading companies. You will find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 East Asian Pharmaceutical Market Overview
  • 1.2 East Asian Pharmaceutical Market Report Segmentation
  • 1.3 Why You Should Read This Report?
  • 1.4 How This Report Delivers
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report For?
  • 1.7 Methodology
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain
  • 1.11 Exchange Rates

2. Introduction to the East Asian Pharmaceutical Market

  • 2.1 National Market Definitions
    • 2.1.1 Japan
    • 2.1.2 Taiwan
    • 2.1.3 Korea
  • 2.2 Other Pharmaceutical Market Definitions
    • 2.2.1 Originator Drugs
    • 2.2.2 Generic Drugs (Generics)
    • 2.2.3 OTC (Over-The-Counter)
    • 2.2.4 Biosimilars
  • 2.3 Introduction to the Global Pharmaceutical Market: A Brief Overview
  • 2.4 Pharmaceutical Approval Regulations
    • 2.4.1 Japan
    • 2.4.2 Taiwan
    • 2.4.3 Korea
  • 2.5 The East Asian Pharmaceutical Market Forecast, 2016-2026

3. The Japanese Pharmaceutical Market

  • 3.1 The Japanese Healthcare System
    • 3.1.1 Costing and Healthcare Delivery
    • 3.1.2 Increasing Generic Penetration: A Matter of Government Policy
    • 3.1.3 Health Technology Assessments
  • 3.2 The Japanese Pharmaceutical Market 2014 and 2015
    • 3.2.1 The Japanese Pharmaceutical Market Forecast, 2016-2026
  • 3.3 The Japanese Pharmaceutical Market 2016-2026: Submarket Shares
  • 3.4 The Japanese Generic Drugs Market 2014
    • 3.4.1 Public Perception Of Generics In Japan
    • 3.4.2 The Japanese Generic Drugs Market Forecast, 2016-2026
  • 3.5 The Japanese Originator Drugs Market 2014
    • 3.5.1 The Japanese Originator Drugs Market Forecast, 2016-2026
  • 3.6 The Japanese OTC Drugs Market 2014 and 2015
    • 3.6.1 The Japanese OTC Drugs Market Forecast, 2016-2026
  • 3.7 The Japanese Biosimilar Drugs Market 2014 and 2015
    • 3.7.1 The Japanese Biosimilar Drugs Market Forecast, 2016-2026

4. Qualitative Analysis of the Japanese Pharmaceutical Market

  • 4.1 SWOT Analysis of The Japanese Pharmaceutical Market, 2016-2026
    • 4.1.1 Strengths
      • 4.1.1.1 Affinity for Branded Products Helping Maintain Revenues
      • 4.1.1.2 High Utilisation of Healthcare Facilities
      • 4.1.1.3 Ageing Population Driving Demand
    • 4.1.2 Weaknesses
      • 4.1.2.1 Reduced Profit Margins Due to Government Pricing
      • 4.1.2.2 Increasing Penetration of Generics Eroding Off-Patent Originator Revenues
      • 4.1.2.3 Restrictions of the OTC Market and Low Consumer Desire
    • 4.1.3 Opportunities
      • 4.1.3.1 Ageing Population Resulting in Increased Demand For High-End Pharmaceuticals
      • 4.1.3.2 New Regulation Allowing for Expansion of the Regenerative Medicine Sector - Sakigake Reforms
      • 4.1.3.3 Increased Trade Opportunities via the Trans-Pacific Partnership (TPP)
    • 4.1.4 Threats
      • 4.1.4.1 Possible Funding Issues Due to Demographics
      • 4.1.4.2 Expanded Use of Biosimilars May Erode Pharmaceutical Market Revenues
  • 4.2 Porter's Five Forces Analysis of the Japanese Pharmaceutical Market
    • 4.2.1 Rivalry Among Competitors [Medium]
    • 4.2.2 Threat of New Entrants [Medium]
    • 4.2.3 Power of Buyers [Medium]
    • 4.2.4 Power of Suppliers [Medium]
    • 4.2.5 Threat of Substitutes [Medium]
  • 4.3 Leading Japanese Domestic Pharmaceutical Companies
    • 4.3.1 Takeda
      • 4.3.1.1 Litigation Regarding ACTOS in the US
    • 4.3.2 Astellas Pharma
    • 4.3.3 Otsuka Pharmaceuticals
    • 4.3.4 Daiichi Sankyo
    • 4.3.5 Eisai Co.

5. The Taiwanese Pharmaceutical Market

  • 5.1 The Taiwanese Healthcare System
    • 5.1.1 Costing and Healthcare Delivery
    • 5.1.2 Health Technology Assessments
  • 5.2 The Taiwanese Pharmaceutical Market 2014 and 2015
    • 5.2.1 The Taiwanese Pharmaceutical Market Forecast, 2016-2026
  • 5.3 The Taiwanese Pharmaceutical Market 2016-2026: Submarket Shares
  • 5.4 The Taiwanese Generic Drugs Market 2014 and 2015
    • 5.4.1 The Taiwanese Generic Drugs Market Forecast, 2016-2026
  • 5.5 The Taiwanese Originator Drugs Market 2014 and 2015
    • 5.5.1 The Taiwanese Originator Drugs Market Forecast, 2016-2026
  • 5.6 The Taiwanese OTC Drugs Market 2014 and 2015
    • 5.6.1 The Taiwanese OTC Drugs Market Forecast, 2016-2026
  • 5.7 The Taiwanese Biosimilar Drugs Market 2014 and 2015
    • 5.7.1 The Taiwanese Biosimilar Drugs Market Forecast, 2016-2026

6. Qualitative Analysis of the Taiwanese Pharmaceutical Market

  • 6.1 SWOT Analysis of The Japanese Pharmaceutical Market, 2016-2026
    • 6.1.1 Strengths
      • 6.1.1.1 Stable Levels of NHI Funding
      • 6.1.1.2 High Trust and Utilisation of Healthcare Facilities
      • 6.1.1.3 Increasingly Aged Population
    • 6.1.2 Weaknesses
      • 6.1.2.1 Strong Presence of Traditional Medicines
      • 6.1.2.2 Political Isolation and Lack of Bilateral Trade Deals
    • 6.1.3 Opportunities
      • 6.1.3.1 Ageing Population and Associated Pharmaceutical Demand Set to Increase
      • 6.1.3.2 Newly Elected Government Promises Support for Pharmaceutical and Biotechnology Industries
      • 6.1.3.3 The Promotion of Taiwan as a Destination for Medical Tourism
    • 6.1.4 Threats
      • 6.1.4.1 The Influence of China on Taiwanese International Relations
      • 6.1.4.2 Rapid Growth of Pharmaceutical Markets in Rival Asian Countries
  • 6.2 Porter's Five Forces Analysis of the Taiwanese Pharmaceutical Market
    • 6.2.1 Rivalry Among Competitors [Medium]
    • 6.2.2 Threat of New Entrants [Low]
    • 6.2.3 Power of Buyers [High]
    • 6.2.4 Power of Suppliers [Low]
    • 6.2.5 Threat of Substitutes [High]
  • 6.3 Leading Taiwanese Pharmaceutical Companies
    • 6.3.1 Standard Chem and Pharma Co. (SCP)
    • 6.3.2 Chunghwa Chemical and Pharmaceutical Co.
    • 6.3.3 Yung Shin Pharmaceutical Industry
    • 6.3.4 TWi Biotechnology
    • 6.3.5 OBI Pharmaceutical

7. The Korean Pharmaceutical Market

  • 7.1 The Korean Healthcare System
    • 7.1.1 Costing and Healthcare Delivery
  • 7.2 The Korean Pharmaceutical Market 2014 and 2015
    • 7.2.1 The Korean Pharmaceutical Market Forecast, 2016-2026
  • 7.3 The Korean Pharmaceutical Market 2016-2026: Submarket Shares
  • 7.4 The Korean Generic Drugs Market 2014 and 2015
    • 7.4.1 Pharmaceutical Price Controls and Measures Being Implemented In South Korea
    • 7.4.2 KORUS FTA: The Free Trade Agreement Between South Korea And The US
    • 7.4.3 The Free Trade Agreement between Korea And The European Union
    • 7.4.4 The Korean Generic Drugs Market Forecast, 2016-2026
  • 7.5 The Korean Originator Drugs Market 2014 and 2015
    • 7.5.1 The Korean Originator Drugs Market Forecast, 2016-2026
  • 7.6 The Korean OTC Drugs Market 2014 and 2015
    • 7.6.1 The Korean OTC Drugs Market Forecast, 2016-2026
  • 7.7 The Korean Biosimilar Drugs Market 2014 and 2015
    • 7.7.1 The Korean Biosimilar Drugs Market Forecast, 2016-2026

8. Qualitative Analysis of the Taiwanese Pharmaceutical Market

  • 8.1 SWOT Analysis of The Japanese Pharmaceutical Market, 2016-2026
    • 8.1.1 Strengths
      • 8.1.1.1 Increasing Strength of Domestic Companies
      • 8.1.1.2 Most Rapidly Ageing Population in the World
      • 8.1.1.3 High Rate of OTC Use Among Population
    • 8.1.2 Weaknesses
      • 8.1.2.1 Funding for Healthcare Becoming Stretched and Pharmaceutical Pricing Pressure
      • 8.1.2.2 Export Prices Based on Domestic Reimbursement
    • 8.1.3 Opportunities
      • 8.1.3.1 Ageing Population Will Result in Increased Expenditure
      • 8.1.3.2 Increasing Level of International Sales for Domestic Companies
      • 8.1.3.3 Korea has Registered Interest in Joining the TPP
    • 8.1.4 Threats
      • 8.1.4.1 Korea is Highly Reliant on Other Countries for its Economic Growth
      • 8.1.4.2 Continued Pricing Pressure
  • 8.2 Porter's Five Forces Analysis of the Korean Pharmaceutical Market
    • 8.2.1 Rivalry Among Competitors [Medium]
    • 8.2.2 Threat of New Entrants [Medium]
    • 8.2.3 Power of Buyers [High]
    • 8.2.4 Power of Suppliers [Low]
    • 8.2.5 Threat of Substitutes [High]
  • 8.3 Leading Korean Pharmaceutical Companies
    • 8.3.1 Daewoong Pharmaceutical Co.
    • 8.3.2 Samsung Bioepis
    • 8.3.3 Celltrion

9. Interviews

  • 9.1 Interview with Sawai Pharmaceuticals, Tokyo, Japan
    • 9.1.1 State of the Pharmaceutical Market in Japan
    • 9.1.2 Current Challenges Facing the Market
    • 9.1.3 Area with Highest Potential for Growth
    • 9.1.4 Effect of Government Policy
    • 9.1.5 Effect of the TPP
    • 9.1.6 Opinions on the Taiwanese and Korean Pharmaceutical Markets

10. Conclusions

  • 10.1 The East Asian Pharmaceutical Market
    • 10.1.1 Ageing Population and Increased Healthcare Spending Pressure
    • 10.1.2 Slowing Economic Growth
  • 10.2 The Japanese Pharmaceutical Market
  • 10.3 The Taiwanese Pharmaceutical Market
  • 10.4 The Korean Pharmaceutical Market

List of Tables

  • Table 1.1 Currency Exchange Rates, 2015
  • Table 2.1 Market Share (%) of the Global Pharmaceutical Market by Region, 2014
  • Table 2.2 The East Asian Pharmaceutical Market Forecast by Country: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 3.1 The Japanese Pharmaceutical Market Forecast by Submarket: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 3.2 The Japanese Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 3.3 The Japanese Originator Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 3.4 The Japanese OTC Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 3.5 The Japanese Biosimilar Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 4.1 SWOT Analysis of the Japanese Pharmaceutical Market, 2016-2026
  • Table 4.2 Takeda Pharmaceutical Company Overview
  • Table 4.3 Astellas Pharma Overview
  • Table 4.4 Otsuka Pharmaceuticals Overview
  • Table 4.5 Daiichi Sankyo Overview
  • Table 4.6 Eisai Co Overview
  • Table 5.1 The Taiwanese Pharmaceutical Market Forecast by Submarket: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 5.2 The Taiwanese Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 5.3 The Taiwanese Originator Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 5.4 The Taiwanese OTC Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 5.5 The Taiwanese Biosimilar Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 6.1 SWOT Analysis of the Taiwanese Pharmaceutical Market, 2016-2026
  • Table 6.2 Standard Chem and Pharma Co. Overview
  • Table 6.3 Chunghwa Chemical and Pharmaceutical Co. Overview
  • Table 6.4 Yung Shin Pharmaceutical Industry Overview
  • Table 6.5 TWi Biotechnology Overview
  • Table 6.6 OBI Pharmaceutical Overview
  • Table 7.1 The Korean Pharmaceutical Market Forecast by Submarket: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 7.2 The Korean Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 7.3 The Korean Originator Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 7.4 The Korean OTC Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 7.5 The Korean Biosimilar Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 8.1 SWOT Analysis of the Korean Pharmaceutical Market, 2016-2026
  • Table 8.2 Daewoong Pharmaceutical Co. Overview
  • Table 8.3 Samsung Bioepis Overview
  • Table 8.4 Celltrion Overview
  • Table 10.1 East Asian Pharmaceutical Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2026

List of Figures

  • Figure 1.1 Key Markets within the East Asian Pharmaceutical Market
  • Figure 2.1 Market Shares (%) of Pharmaceutical Market by Region, 2014
  • Figure 2.2 New Drug Regulatory Approval Pathway, Taiwan, 2016
  • Figure 3.1 The Japanese Pharmaceutical Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 3.2 The Japanese Pharmaceutical Market Submarkets by Revenue Share (%), 2014
  • Figure 3.3 The Japanese Pharmaceutical Market Submarkets by Revenue Share (%), 2020
  • Figure 3.4 The Japanese Pharmaceutical Market Submarkets by Revenue Share (%), 2026
  • Figure 3.5 The Japanese Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 3.6 The Japanese Originator Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 3.7 The Japanese OTC Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 3.8 The Japanese Biosimilar Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 4.1 A Comparison of the Updated and Previous Regulations Regarding Regenerative Medicine Testing in Japan
  • Figure 4.2 Porter's Five Forces Analysis of the Japanese Pharmaceutical Market, 2016-2026
  • Figure 5.1 The Taiwanese Pharmaceutical Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 5.2 The Taiwanese Pharmaceutical Market Submarkets by Revenue Share (%), 2014
  • Figure 5.3 The Taiwanese Pharmaceutical Market Submarkets by Revenue Share (%), 2020
  • Figure 5.4 The Taiwanese Pharmaceutical Market Submarkets by Revenue Share (%), 2026
  • Figure 5.5 The Taiwanese Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 5.6 The Taiwanese Originator Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 5.7 The Taiwanese OTC Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 5.8 The Taiwanese Biosimilar Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 6.1 Porter's Five Forces Analysis of the Taiwanese Pharmaceutical Market, 2016-2026
  • Figure 7.1 The Korean Pharmaceutical Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 7.2 The Korean Pharmaceutical Market Submarkets by Revenue Share (%), 2014
  • Figure 7.3 The Korean Pharmaceutical Market Submarkets by Revenue Share (%), 2020
  • Figure 7.4 The Korean Pharmaceutical Market Submarkets by Revenue Share (%), 2026
  • Figure 7.5 The Korean Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 7.6 The Korean Originator Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 7.7 The Korean OTC Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 7.8 The Korean Biosimilar Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 8.1 Porter's Five Forces Analysis of the Korean Pharmaceutical Market, 2016-2026
  • Figure 10.1 East Asian Pharmaceutical Market Forecast: Revenue ($bn) and AGR (%), 2014-2026

Companies Listed

  • Actavis
  • Ambit Biosciences
  • ASKA Pharmaceuticals
  • Astellas Pharma
  • Astex Pharmaceuticals
  • Avanir Pharmaceuticals
  • Biogen Idec
  • Breckenridge Pharmaceutical
  • Celltrion
  • Chunghwa Chemical and Pharmaceutical Co.
  • Daewoong Co. Ltd.
  • Daewoong Pharmaceutical Co.
  • Daiichi Sankyo
  • Dainippon Sumimoto Pharma
  • Dalim BioTech
  • Eisai Co.
  • Elyson Pharmaceuticals
  • Fujifilm Corporation
  • Fujisawa Pharmaceuticals
  • Ilsung Pharmaceuticals
  • JHL Biotech
  • KMS Pharmaceutical
  • LEO Pharma
  • Merck MSD
  • Novartis
  • OBI Pharmaceutical
  • Ocata Therapeutics
  • OSI Pharmaceutical
  • Otsuka Pharmaceuticals
  • PharmaEngine
  • Ranbaxy
  • Samsung
  • Samsung Bioepis
  • Samsung Biologics
  • Sandoz (Novartis)
  • Sawai Pharmaceutical
  • Standard Chem and Pharma Company
  • Sun Pharmaceuticals
  • Takeda Pharmaceutical
  • Teva
  • TWi Biotechnology
  • Yamanouchi Pharmaceuticals
  • Yung Shin Pharmaceutical Industry

Organisations Mentioned in the Report

  • Academia Sinica
  • Central Social Insurance Medical Council - Japan
  • Democratic Progressive Party - Taiwan
  • European Medicines Agency
  • Joint Commission International
  • Korean Food and Drug Administration
  • Kuomingtang - Taiwan
  • Ministry of Food and Drug Safety - Korea
  • Ministry of Health and Welfare - Korea
  • Ministry of Health and Welfare - Taiwan
  • Ministry of Health, Labour and Welfare - Japan
  • National Health Service - UK
  • National Institute of Clinical Excellence - UK
  • Pharmaceutical and Medical Devices Agency - Japan
  • Taiwan Food and Drug Administration
  • Trans-Pacific Partnership
  • US Food and Drug Administration
  • World Trade Organisation
Back to Top